EP3157958A1 - Cellules nk-92 exprimant car comme agents thérapeutiques cellulaires - Google Patents

Cellules nk-92 exprimant car comme agents thérapeutiques cellulaires

Info

Publication number
EP3157958A1
EP3157958A1 EP15730150.8A EP15730150A EP3157958A1 EP 3157958 A1 EP3157958 A1 EP 3157958A1 EP 15730150 A EP15730150 A EP 15730150A EP 3157958 A1 EP3157958 A1 EP 3157958A1
Authority
EP
European Patent Office
Prior art keywords
cell
cells
erbb2
cancer
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15730150.8A
Other languages
German (de)
English (en)
Other versions
EP3157958B1 (fr
Inventor
Winfried Wels
Kurt SCHÖNFELD
Torsten Tonn
Manuel Grez
Congcong ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
DRK Blutspendedienst Baden Wuerttermberg Hessen gGmbH
Original Assignee
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
DRK Blutspendedienst Baden Wuerttermberg Hessen gGmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemotherapeutisches Forschungsinstitut Georg Speyer Haus, DRK Blutspendedienst Baden Wuerttermberg Hessen gGmbH filed Critical Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Publication of EP3157958A1 publication Critical patent/EP3157958A1/fr
Application granted granted Critical
Publication of EP3157958B1 publication Critical patent/EP3157958B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome.
  • the present invention further relates to the use of the ErbB2- specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers.
  • the present invention further relates to the use of the ErbB2- specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy.
  • the present invention further relates to a method for generating an ErbB2- specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK- 92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
  • NK cells are an important effector cell type for adoptive cancer immunotherapy. Similar to T cells, NK cells can be modified to express chimeric antigen receptors (CARs) to enhance antitumor activity.
  • CARs chimeric antigen receptors
  • NK cells play an important role in cancer immunosurveillance, and represent an important effector cell type for adoptive cancer immunotherapy (Geller and Miller, 2011). In contrast to T cells, they do not require prior sensitization and recognition of peptide antigens presented in complex with MHC molecules.
  • the present invention aims to provide improved CAR-engineered NK cells, which are suitable for clinical use, in particular in the treatment of cancers and as targeted cell therapeutic agents.
  • an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor (CAR) comprising
  • an ErbB2-specific scFv antibody fragment a hinge region, transmembrane and intracellular domains of CD28, and intracellular domain of CD3 zeta, wherein said vector is genomically integrated (i), preferably in an intergenic region on chromosome 2, and (ii) in the TRAF2 gene on chromosome 9.
  • this object is solved by providing the NK-92 cell or cell line according to the invention for use in medicine. According to the present invention this object is solved by providing the NK-92 cell or cell line according to the invention for use in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers.
  • this object is solved by providing the NK-92 cell or cell line according to the invention for use as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy.
  • this object is solved by a method for generating an ErbB2- specific NK-92 cell or cell line, comprising the steps of:
  • this object is solved by a method for identifying an ErbB2- specific NK-92 cell or cell line, comprising the steps of:
  • this object is solved by an NK-92 cell or cell line obtained or identified by the methods according to the invention. According to the present invention this object is solved by providing the NK-92 cell or cell line obtained or identified by the methods according to the invention for use in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers.
  • this object is solved by providing the NK-92 cell or cell line obtained or identified by the methods according to the invention for use as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy.
  • the present invention provides an ErbB2-specific NK-92 cell or cell line
  • the ErbB2-specific NK-92 cell or cell line of the present invention contains
  • a lentiviral vector encoding a chimeric antigen receptor comprising
  • an ErbB2-specific scFv antibody fragment an ErbB2-specific scFv antibody fragment, a hinge region, transmembrane and intracellular domains of CD28, and intracellular domain of CD3 zeta.
  • the ErbB2-specific NK-92 cell or cell line preferably contains two vector integration loci in its cellular genome.
  • the ErbB2-specific NK-92 cell or cell line is characterized in that said vector is genomically integrated (i), preferably in an intergenic region on chromosome 2, and (ii) in the TRAF2 gene on chromosome 9.
  • the unmodified NK-92 cell or cell line is known in the art. See e.g. Gong et al., 1994 or WO 98/49268 Al . NK-92 cells are deposited with the American Type Tissue Collection (ATCC no. CRL-2407).
  • the ErbB2-specific NK-92 cell or cell line can be molecularly characterized and identified by said two vector integrations.
  • the NK-92 cell or cell line of the present invention is characterized in that by PCR analysis of the genomic DNA of said cell or cell line at least one of the following amplification products is/are obtained:
  • PCR analysis of genomic DNA of the cell or cell line of the invention with oligonucleotide primers hybridizing to genomic and vector DNA sequences adjacent to 5' and 3' junction sites of chromosomal and integrated vector sequences yield amplification products of defined length and sequence (namely the PCR fragments specified in SEQ ID NO. 9, 10, 11, 12), confirming the vector integrations and molecularly identifying the cell (clone) NK-92 of the present invention.
  • Amplification products of defined length and sequence a) Amplification product of CAR vector integration in TRAF2 gene
  • TRAF2-CAR 5' part of vector integration PCR product from genomic DNA of N -92/5-28.Z cells
  • the NK-92 cell or cell line of the present invention is characterized
  • the NK-92 cell or cell line shows reduced or no natural cytotoxicity, i.e. reduced or no cytotoxicity to ErbB2-negative cells which are lysed by unmodified NK-92 cells, and/or
  • the NK-92 cell or cell line shows increased specific cytotoxicity, i.e. increased cytotoxicity to ErbB2-expressing tumor cells compared to unmodified NK-92 cells.
  • Said reduced natural cytotoxicity constitutes an important safety feature of the cell or cell line of the invention, in particular in view of a clinical use.
  • the NK-92 cell or cell line of the present invention in contrast to unmodified NK-92 cells - lyse ErbB2-expressing tumor cells with high efficiency, but are less likely than unmodified NK-92 cells to attack ErbB2-negative non-target cells.
  • the ErbB2-specific scFv antibody fragment comprises or consists of the amino acid sequence of SEQ ID NO. 13 (scFv FRP5) and/or is encoded by the nucleotide sequence of SEQ ID NO. 14.
  • ErbB2-specific scFv FRP5 is further described in EP 2 164 516 Bl and US 7,887,801 B2.
  • Chimeric antigen receptors are known in the art.
  • the ErbB2-specific CAR used in the present invention comprises:
  • the chimeric antigen receptor comprises or consists of the amino acid sequence of SEQ ID NO. 15 and/or is encoded by the nucleotide sequence of SEQ ID NO. 16.
  • Suitable CARs are further described in WO 2012/031744.
  • the CAR-encoding sequence is flanked by 5' and 3' long terminal repeats (LTR) of the vector.
  • NK cells are an important effector cell type for adoptive cancer immunotherapy. Similar to T cells, NK cells can be modified to express chimeric antigen receptors (CARs) to enhance antitumor activity, but experience with CAR-engineered NK cells is limited and data on clinical development are lacking. Here, the inventors redirected clinically usable human NK-92 cells to the tumor-associated ErbB2 (HER2) antigen expressed at elevated levels by many cancers of epithelial origin.
  • CARs chimeric antigen receptors
  • the inventors Following GMP-compliant procedures, the inventors generated an NK-92/5.28.Z single cell clone expressing an ErbB2-specific CAR with CD28 and ⁇ 3 ⁇ signaling domains.
  • Vector integrations in the NK-92/5.28.Z cell clone were mapped by linear amplification- mediated PCR and DNA sequencing following established procedures (Schmidt et al., 2003), which revealed one vector integration each in an intergenic region on chromosome 2, and in the TRAF2 gene on chromosome 9.
  • PCR analysis of genomic DNA with oligonucleotide primers hybridizing to genomic and vector DNA sequences adjacent to 5' and 3' junction sites of chromosomal and integrated vector sequences e.g. the oligonucleotide primers specified in SEQ ID NO. 1 and 2, 3 and 4, 5 and 6, 7 and 8) yield amplification products of defined length and sequence (e.g. the PCR fragments specified in SEQ ID NO. 9, 10, 11, 12), confirming the vector integrations and molecularly identifying the cell clone NK- 92/5.28.Z.
  • NK-92/5.28.Z cells efficiently lysed ErbB2-expressing and otherwise N -resistant tumor cells in vitro, but did not lyse ErbB2-negative cells resistant to unmodified NK-92. Unexpectedly, NK-92/5.28.Z cells also displayed reduced cytotoxicity to ErbB2-negative cells which are readily lysed by unmodified NK-92 cells. This constitutes an important safety feature of NK- 92/5.28.z cells which in contrast to unmodified NK-92 cells lyse ErbB2-expressing tumor cells with high efficiency, but are less likely than unmodified NK-92 cells to attack ErbB2- negative non-target cells.
  • NK-92/5.28.Z cells Specific recognition of tumor cells and antitumor activity were retained in vivo, resulting in homing of NK-92/5.28.Z cells to orthotopic breast carcinoma xenografts and reduction of pulmonary metastasis of renal cell carcinoma cells, ⁇ -irradiation as a potential safety measure for clinical application prevented replication of the cells, while in vitro and in vivo antitumoral activity were preserved.
  • a particularly preferred ErbB2-specific NK-92 cell or cell line of the invention is the NK-92 cell or cell line identified as NK-92/5.28.Z which was deposited on June 11, 2014 at the Leibniz Institute DSMZ - German Collection of Microorganisms and Cell Cultures GmbH, Inhoffenstr. 7B, 38124 Braunschweig, Germany, under accession number DSM ACC3244.
  • the present invention demonstrates that it is feasible to engineer CAR-expressing NK cells as a clonal, molecularly and functionally well-defined and continuously expandable cell therapeutic agent, and suggest NK-92/5.28.Z cells as a promising candidate for clinical development.
  • the present invention provides the ErbB2-specific NK-92 cell or cell line according to the invention for use in medicine.
  • the present invention provides the NK-92 cell or cell line according to the invention for use in the prevention and/or treatment of cancer, preferably ErbB2- expressing cancers.
  • the cancer preferably the ErbB2-expressing cancers, is/are selected from
  • the cells are pre-treated by irradiation, preferably by ⁇ -irradiation. Said irradiation may be included as a safety measure.
  • the present invention provides the NK-92 cell or cell line according to the invention for use as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy.
  • a “cell therapeutic agent”, in particular a “targeted cell therapeutic agent” or “targeted allogeneic cell therapeutic agent” refers to an immune cell suitable for application for adoptive cancer immunotherapy, which is genetically modified to express an antigen receptor that specifically recognizes a defined antigen expressed on the surface of a target tumor cell.
  • “Adoptive, target-cell specific immunotherapy” or “adoptive cancer immunotherapy” or “adoptive cell therapy (ACT)” refers to a form of therapy in which immune cells are transferred to tumor-bearing hosts. The immune cells have antitumor reactivity and can mediate direct or indirect antitumor effects.
  • NK-92 cells with CARs such as provided by this invention, is very suitable for ACT and the treatment of cancer.
  • the use comprises a pre-treatment of the cells by irradiation, preferably ⁇ - irradiation.
  • Said irradiation may be included as a safety measure.
  • the present invention provides a method for generating an ErbB2-specific NK-92 cell or cell line.
  • Said methods further allows to molecularly identify the ErbB2-specific NK-92 cell or cell line generated.
  • Said method comprises the steps of:
  • the vector for transducing NK-92 cells of step (1) is an integrating vector, preferably a lentiviral vector.
  • the lentiviral vector encodes a chimeric antigen receptor (CAR) comprising
  • the lentiviral vector can be generated following established methodology known to a skilled person.
  • a suitable example for an ErbB2-specific scFv antibody fragment is scFv FRP5.
  • the ErbB2-specific scFv antibody fragment comprises or consists of the amino acid sequence of SEQ ID NO. 13 (scFv FRP5) and/or is encoded by the nucleotide sequence of SEQ ID NO. 14.
  • ErbB2-specific scFv FRP5 is further described in EP 2 164 516 Bl and US 7,887,801 B2.
  • Chimeric antigen receptors are known in the art.
  • the ErbB2-specific CAR used in the present invention comprises:
  • the chimeric antigen receptor comprises or consists of the amino acid sequence of SEQ ID NO. 15 and/or is encoded by the nucleotide sequence of SEQ ID NO. 16.
  • CARs chimeric antigen receptors
  • ErbB2-specific scFv antibody fragment Suitable examples for chimeric antigen receptors (CARs) comprising an ErbB2-specific scFv antibody fragment are further known, such as described in WO 2012/031744.
  • Step (1) preferably comprises producing VSV-G pseudotyped lentiviral vector particles.
  • Step (2) is preferably carried out by following GMP-compliant procedures.
  • the NK-92 cells of step (2) are preferably human NK-92 cells.
  • Step (5) preferably comprises selecting cell clone(s) which display high and stable CAR- expression during continuous culture.
  • Steps (6) and (7) comprise in vitro cytotoxicity assays, such as FACS based assays, preferably carried out at different effector to target ratios (E/T).
  • E/T effector to target ratios
  • Suitable ErbB2-expressing cells are ErbB2-expressing tumor cells, such as murine renal cell carcinoma cells stably expressing human ErbB2 (Renca-lacZ/ErbB2) or MDA-MB453 human breast carcinoma cells (ATCC no. HTB-131).
  • Said ErbB2-negative cells are used for evaluating or testing the specific cytotoxicity of the cell clones.
  • Suitable ErbB2-negative cells are NK-sensitive but ErbB2-negative cells, such as human K562 erythroleukemia cells (ATCC no. CCL-243).
  • Said ErbB2-negative cells are used for evaluating or testing the natural cytotoxicity / endogenous, CAR-independent cytotoxicity of the cell clones.
  • the cytotoxicity assays in step (6) and/or (7) are preferably also carried out with unmodified NK-92 cells (ATCC no. CRL-2407) and the results are compared with the results of the tested cell clones.
  • step (8) the cell clone(s) are selected which display high cytotoxicity against ErbB2- expressing cells and low or no cytotoxicity against ErbB2-negative cells.
  • Step (9) preferably comprises deteraiining number and position of vector integration by linear amplification-mediated PCR (LAM-PCR) and DNA sequencing, and confirmation by PCR analysis of genomic DNA.
  • LAM-PCR linear amplification-mediated PCR
  • Suitable primers for the PCR analysis of genomic DNA and their respective amplification products are, for example (in an embodiment with a lentiviral vector):
  • Vector integration site CAR vector integration in intergenic region of chromosome 2:
  • CAR-F2 IGCHR2 CAR-R1: IGCHR2-CAR ACTGATAATTCCGTGGTGTTGT CACTGTGGCTCACTGCTAGA (3')
  • the present invention provides an NK-92 cell or cell line obtained by the method according to the invention.
  • the present invention provides a method for identifying an ErbB2- specific NK-92 cell or cell line.
  • Said method comprises the steps of:
  • the method preferably comprises detennining number and position of vector integration by linear amplification-mediated PCR (LAM-PCR) and DNA sequencing, and confirmation by PCR analysis of genomic DNA.
  • LAM-PCR linear amplification-mediated PCR
  • Suitable primers for the PCR analysis of genomic DNA and their respective amplification products are, for example (in an embodiment with a lentiviral vector), as described above.
  • the cell (clone) is characterized in that by PCR analysis of the genomic DNA of said cell (clone) at least one of the following amplification products is obtained:
  • - PCR with primers of SEQ ID NOs. 5 and 6 yields an amplification product with the nucleotide sequence of SEQ ID NO. 1 1 ;
  • - PCR with primers of SEQ ID NOs. 7 and 8 yields an amplification product with the nucleotide sequence of SEQ ID NO. 12.
  • the present invention provides an NK-92 cell or cell line identified by the method according to the invention.
  • the present invention provides the NK-92 cell or cell line obtained or identified by the methods according to the invention for use in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers.
  • the cancer preferably the ErbB2-expressing cancers, is/are selected from:
  • the cells are pre-treated by irradiation, preferably by ⁇ -irradiation. Said irradiation may be included as a safety measure.
  • the present invention provides the NK-92 cell or cell line obtained or identified by the methods according to the invention for use as targeted (allogeneic) cell therapeutic agent and/or for adoptive cancer immunotherapy.
  • the use comprises a pre-treatment of the cells by iiTadiation, preferably ⁇ - irradiation.
  • Said irradiation may be included as a safety measure.
  • this object is solved by a method for the prevention and/or treatment of cancer (herein after "treatment method").
  • the cancer is preferably the ErbB2-expressing cancers, which is/are preferably selected from:
  • said treatment method comprises or includes adoptive cancer immunotherapy.
  • Said treatment method comprises
  • a "therapeutically effective amount" of the NK-92 cells of this invention refers to the amount that is sufficient to treat the respective disease (cancer) or achieve the respective outcome of the adoptive, target-cell specific immunotherapy.
  • CAR-engineered NK-92 cells were developed as a targeted allogeneic cell therapeutic agent.
  • NK-92/5.28.Z cells were derived from a single cell clone after lentiviral transduction with a vector encoding a second generation CAR that targets the ErbB2 (HER2) receptor tyrosine kinase, a tumor-associated self-antigen expressed at elevated levels by many human cancers of epithelial origin (Hynes and Lane, 2005).
  • ErbB2-specific NK-92/5.28.Z cells efficiently lysed ErbB2-expressing tumor cells in vitro that were resistant to unmodified NK-92 cells. Importantly, specific recognition of ErbB2-positive tumor cells and antitumoral activity were retained in vivo, resulting in homing of NK- 92/5.28.Z cells to orthotopic breast carcinoma xenografts and reduction of pulmonary metastasis of renal cell carcinoma cells in murine models.
  • NK-92 cells demonstrate successful targeting of human NK-92 cells to the tumor-associated cell surface antigen ErbB2 by expression of a humanized and codon-optimized second-generation CAR.
  • GMP-compliant procedures we established from a molecularly defined single cell clone a continuously expanding CAR- modified cell line suitable for clinical development.
  • NK-92/5.28.Z cells display stable CAR expression upon prolonged culture and target-antigen-specific cytotoxicity in vitro and in. vivo.
  • NK-92/5.28.Z cells retain target cell specificity in vivo, and are capable of penetrating tissues and homing to distant tumor sites.
  • intravenous injection of NK-92/5.28.Z cells reduced metastasis formation in different experiments by 50% or more, while unmodified NK-92 cells failed to affect outgrowth of pulmonary tumor nodules.
  • NK-92/5.28.Z cells irradiated with 10 Gy was the same as that of non-irradiated cells. This may be relevant for future clinical application of NK-92/5.28.Z, where irradiation of cells may be included as a safety measure as previously done in phase I clinical trials with unmodified NK-92 cells (Arai et al. 2008; Tonn et al., 2013).
  • Immune cells in tumor patients are often functionally compromised due to the immunosuppressive activity of the cancer.
  • donor-derived allogeneic cells are being preferred since they do not recognize tumor cells as 'self, thereby bypassing inhibitory signals (Geller and Miller, 2011).
  • this advantage can be extended to CAR-engineered NK-92 cells.
  • Figure 1 Chimeric antigen receptor expression and selective cytotoxicity of clonal NK- 92/5.28.z cells.
  • CAR 5.28.Z consists of an immunoglobulin heavy chain signal peptide (SP), the ErbB2 ⁇ specific scFv (FRP5) antibody fragment (scFv), a hinge region (CD8a), followed by transmembrane and intracellular domains of CD28 and the intracellular domain of ⁇ 3 ⁇ .
  • the CAR-encoding sequence is flanked by 5' and 3' long terminal repeats (LTR) of the vector (not shown).
  • LTR long terminal repeat
  • NK-92/5.28.Z cells were irradiated with 5 or 10 Gy and cultured for up to 72 hours. Proliferation was analyzed by counting viable cells at the indicated time points using trypan blue exclusion.
  • FIG. 4 Homing ofNK-92/5.28.z cells to ErbB2-positive breast carcinomas in vivo.
  • Unmodified NK-92 (upper panel) or ErbB2-specific NK-92/5.28.Z cells (lower panel) were labeled with fluorescent DiD labeling reagent and intravenously injected into NSG mice carrying established orthotopic MDA-MB453/EGFP breast carcinoma xenografts. Twenty- four hours after injection, tumors were excised, single cell suspensions were prepared, and analyzed for the presence of EGFP-expressing and DiD-labeled cells. DiD-positive NK cells are indicated in dark grey (lower right quadrants).
  • EGFP -positive breast carcinoma cells upper left quadrants
  • double-negative murine stromal cells lower left quadrants
  • Double-positive events upper right quadrant
  • NSG mice were intravenously injected with Renca- lacZ/ErbB2 renal cell carcinoma cells. Then animals were treated twice by i.v. injection of unmodified NK-92 or clonal NK-92/5.28.Z cells at days 1 and 3 after tumor cell injection. Control mice received PBS. Four weeks after tumor challenge, lungs were excised and tumor nodules on the lung surface were counted.
  • NSG mice injected with Renca-lacZ/ErbB2 cells were treated as described above with non-irradiated NK-92 or NK-92/5.28.Z cells, or NK-92/5.28.Z cells irradiated with 10 Gy as indicated.
  • Human K562 erythroleukemia cells (ATCC, Manassas, VA) were maintained in RPMI 1640 medium (Lonza, Koln, Germany).
  • Human MDA-MB453 and MDA-MB468 breast carcinoma cells, and HEK 293T cells were cultured in DMEM (Lonza). All media were supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 ⁇ ⁇ ⁇ streptomycin.
  • Human NK-92 cells were propagated in X-VIVO 10 medium (Lonza) supplemented with 5% heat-inactivated human plasma (German Red Cross Blood Service Baden- Wurttemberg - Hessen, Frankfurt, Germany) and 100 IU/ml IL-2 (Proleukin; Novartis Pharma, Nurnberg, Germany).
  • Murine Renca-lacZ/ErbB2 and Renca-lacZ/EGFR renal cell carcinoma cells expressing human ErbB2 or EGFR were cultured in RPMI- 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 0.25 mg/ml zeocin and 0.48 mg/ml G418 (Maurer-Gebhard et al, 1998).
  • the CAR sequence 5.28. ⁇ was designed by in silico assembly of an immunoglobulin heavy chain signal peptide, ErbB2-specific scFv(FRP5) antibody fragment and a modified CD8a hinge region (wherein an unpaired cysteine within the hinge region was replaced by serine), followed by CD28 transmembrane and intracellular domains and ⁇ 3 ⁇ intracellular domain.
  • a codon-optimized fusion gene was synthesized (GeneArt, Regensburg, Germany) and inserted into lentiviral transfer plasmid pHR'SIN-cPPT-WPREmut vector (Schambach et al, 2006), resulting in lentiviral transfer plasmid pS-5.28.z-W.
  • VSV-G pseudotyped vector particles were generated and NK-92 cells were transduced as described previously (Sahm et al, 2012), and for cell clone NK-92/.5.28.Z confirmed by PCR analysis of genomic DNA with oligonucleotide primers that yielded characteristic PCR products spanning the junctions between chromosomal DNA and integrated vector sequences.
  • Cytotoxicity of NK-92 cells towards target cells was analyzed in FACS-based assays as described (Sahm et al., 2012). Briefly, target cells were labeled with calcein violet AM (Molecular Probes, Invitrogen, Düsseldorf, Germany) and co-cultured with effector cells at various effector to target (E/T) ratios for 2 h at 37°C. After co-culture, 250 ⁇ of a 1 ⁇ g/ml propidium iodide (PI) solution were added to each sample 5 min before flow cytometric analysis in a FACSCanto II flow cytometer (BD Biosciences, Heidelberg, Germany). Data were analyzed using FACSDiva software (BD Biosciences). To calculate specific cytotoxicity, the number of spontaneously lysed target cells in the absence of effector cells was subtracted from the number of dead target cells determined as calcein violet AM and PI double positive in the measured sample.
  • PI propidium iodide
  • NK-92/5.28.Z and unmodified NK-92 cells were collected by centrifugation, counted, washed, resuspended in fresh growth medium and irradiated with 5 or 10 Gy using a Biobeam 2000 device (Gamma Service Medical, Leipzig, Germany).
  • irradiated cells were washed, resuspended in fresh growth medium and cultured for up to 72 h. Proliferation was analyzed by counting viable cells at different time points using trypan blue exclusion. For in vivo experiments, cells were irradiated with 10 Gy and applied directly.
  • EGFP-expressing MDA-MB453 breast carcinoma cells were derived by transduction of MDA-MB453 cells with an EGFP-encoding lentiviral vector and enrichment by flow cytometric cell sorting.
  • Orthotopic breast carcinoma xenografts were induced in 4 to 6 weeks old female NOD-SCID IL2R y nu " (NSG) mice (Charles River, Sulzfeld, Germany) by injection of 5 x 10 6 MDA-MB453/EGFP cells suspended in Matrigel (BD Biosciences) into the mammary fat pad.
  • NK-92/5.28.Z or unmodified NK-92 cells were labeled with DiD (l, -dioctadecyl-3,3,3',3' tetramethylindodicarbocyanine) labeling reagent (Molecular Probes/Life Technologies, Darmstadt, Germany) as described (Tavri et al., 2009), and injected into the lateral tail vein of the tumor bearing mice (1 10 cells/animal; 3 animals per group). Twenty-four hours after injection, mice were sacrificed, tumors were excised, single cell suspensions were prepared, and analyzed for the presence of EGFP- expressing and DiD-labeled cells in a FACSCanto II flow cytometer.
  • DiD l, -dioctadecyl-3,3,3',3' tetramethylindodicarbocyanine
  • mice Four to 6 weeks old female NSG mice were injected with 1 x 10 5 Renca-lacZ/ErbB2 cells into the lateral tail vein at day 0. Then animals were treated by i.v. injection of 1 x 10 7 NK- 92/5.28.Z or unmodified NK-92 cells at days 1 and 3 after tumor cell injection (5 mice/group). Control mice received PBS. In separate experiments, NSG mice injected with Renca- lacZ/ErbB2 cells were also treated with irradiated NK-92/5.28.Z cells (10 Gy), or non- irradiated NK-92/5.28.Z and unmodified NK-92 cells as controls (5 mice/group). Four weeks after tumor challenge, all animals were sacrificed, lungs were excised, and tumor nodules on the lung surface were counted as described (Maurer-Gebhard et al., 1998).
  • the chimeric antigen receptor 5.28.Z was used to generate a clinically applicable ErbB2- specific NK-92 cell line ( Figure 1A).
  • VSV-G pseudotyped lentiviral CAR vector particles were produced and NK-92 cells from a certified NK-92 master cell bank (Arai et al., 2008) were transduced.
  • Single cell clones were derived by limiting dilution, and CAR-expressing cells were identified by flow cytometric analysis with ErbB2-Fc fusion protein.
  • a total of 15 CAR-expressing single cell clones were functionally and molecularly characterized, which harbored between one and four vector copies.
  • NK-92/5.28.Z which displayed high and stable CAR-expression during continuous culture in a setting reflecting large-scale expansion under GMP conditions was selected for further analysis (Figure IB).
  • Selective cytotoxic activity of the retargeted cells was evaluated using Renca-lacZ/ErbB2 murine renal cell carcinoma cells stably expressing human ErbB2.
  • Clonal NK-92/5.28.Z cells displayed high cytotoxicity towards these ErbB2-expressing target cells, which were resistant to unmodified NK-92 ( Figure 1C, left panel).
  • ErbB2-negative negative but otherwise isogenic Renca-lacZ/EGFR cells expressing epidermal growth factor receptor displayed no enhanced sensitivity to the effector cells ( Figure 1C, right panel). This indicates that cell killing was indeed mediated by interaction of CAR 5.28.Z with its target antigen ErbB2.
  • NK-92/5.28.Z cells Endogenous, CAR-independent cytotoxicity of NK-92/5.28.Z cells was investigated using ErbB2-neagtive but NK-sensitive K562 human erythroleukemia cells as targets. While K562 cells were highly sensitive to CAR-negative unmodified NK-92 cells, they were killed to a much lower extent by ErbB2-specific NK-92/5.28.Z cells ( Figure ID).
  • NK-92/5.28.Z cells are highly selective and efficiently kill ErbB2-expressing tumor cells, while their endogenous cytotoxicity to ErbB2- negative targets is markedly reduced when compared to unmodified NK-92 cells.
  • Linear amplification-mediated PCR (LAM-PCR) and DNA sequencing revealed one vector integration each in an intergenic region on chromosome 2, and in the TRAF2 gene on chromosome 9 of clonal NK-92/5.28.Z cells ( Figure 2A).
  • the integration sites were confirmed by PCR analysis of genomic DNA of NK-92/5.28.Z cells from three different passages during continuous culture over several months, thereby amplifying specific DNA sequences that encompass the junctions between the TRAF2 gene and the 5' end of the integrated CAR vector, and between the 3' end of the integrated CAR vector and the TRAF2 gene ( Figure 2B, upper panels), as well as specific DNA sequences that encompass the junctions between the intergenic region in chromosome 2 and 5' and 3' ends of the integrated CAR vector ( Figure 2B, lower panels).
  • genomic DNA of the different passages of NK-92/5.28.Z cells yielded the same characteristic amplification products of defined length and sequence, demonstrating long-term stability of the vector integrations.
  • TRAF2-F1 CTTCAGCAGGGACCAGAAACAA [SEQ ID NO. 1]
  • CAR-R1 ccGCTTAATACTGACGCTCTCG [SEQ ID NO. 2] lower case letters: TRAF2 gene
  • CAR-F1 ATCGCCACGGCAGAACTCA [SEQ ID NO. 3]
  • TRAF2-R1 GACCCTTCACCCAACGCTTAG [SEQ ID NO. 4] lower case letters: TRAF2 gene
  • IGCHR2-F1 TCAGTGGAATGGGCAGCTTCAAGT [SEQ ID O. 5]
  • CAR-R2 TTCAGCAAGCCGAGTCCTGCGT [SEQ ID NO. 6] lower case letters: intergenic region chromosome 2
  • CAR-F2 ACTGATAATTCCGTGGTGTTGT [SEQ ID NO. 7]
  • IGCHR2_CAR-R1 CACTGTGGCTCACTGCTAGA [SEQ ID NO. 8] lower case letters: intergenic region chromosome 2
  • vector sequence Length 376 nucleotides
  • NK-92/5.28.Z cells irradiated with 10 Gy were cultured for 24 hours and then co-incubated for two hours with ErbB2-expressing human MDA-MB453 breast carcinoma cells as targets.
  • Irradiated NK-92/5.28.Z displayed high and specific cytotoxicity towards MDA-MB453 cells (65% specific lysis at an E/T ratio of 10:1), while they did not lyse ErbB2-negative human MDA-MB468 breast carcinoma cells (Figure 3B). Neither MDA- MB453 nor MDA-MB468 cells were killed by irradiated unmodified NK-92 cells.
  • NK-92/5.28.Z cells The potential of NK-92/5.28.Z cells to home to established tumors was investigated in an orthotopic breast carcinoma model.
  • MDA-MB453 cells transduced with an EGFP-encoding lenti viral vector were implanted into the mammary fat pad of female NSG mice, and allowed to grow until tumors were palpable.
  • NK-92/5.28.Z and unmodified unmodified NK-92 cells were labeled with fluorescent DiD labeling reagent, and intravenously injected into the tumor-bearing animals. Twenty-four hours later, tumors were excised, single cell suspensions were prepared, and analyzed for the presence of EGFP-expressing tumor cells and DiD- labeled NK cells.
  • NK-92/5.28.Z In mice injected with unmodified NK-92, only a few of the NK cells were found in the tumors ( Figure 4, upper panel). In contrast, ⁇ -92/5.28. ⁇ cells were strongly enriched in MDA-MB453/EGFP xenografts ( Figure 4, lower panel). Importantly, we also found conjugates of NK-92/5.28.Z and MDA-MB453/EGFP cells in the cell suspensions prepared from the tumors. These data demonstrate that NK-92/5.28.Z cells retain target cell specificity in vivo, and are capable of penetrating tissues and homing to distant tumor sites.
  • mice received intravenous injections of Renca-lacZ/ErbB2 cells, followed by i.v. injections of unmodified NK-92 or retargeted NK-92/5.28.Z cells at days 1 and 3 after tumor cell inoculation.
  • Control mice received PBS.
  • lungs were excised and tumor nodules on the lung surface were counted.
  • NK-92/5.28.Z cells reduced the number of pulmonary tumor nodules in this experiment by approximately 50% (mean number of lung surface metastases: PBS: 37.7 ⁇ 5.4; NK-92: 36 ⁇ 5.1 ; NK-92/5.28.z: 19 ⁇ 2.6; ⁇ 0.05) (Figure 5A).
  • NK- 92/5.28.z cells retain in vivo antitumor activity after ⁇ -irradiation, a similar experiment was performed employing NK-92/5.28.Z cells that were irradiated with 10 Gy prior to injection.
  • Control animals were treated with non-irradiated NK-92/5.28.Z or non-irradiated unmodified NK-92 cells.
  • both, non-irradiated and irradiated NK-92/5.28.Z cells markedly reduced the number of pulmonary tumor nodules (mean number of lung surface metastases: NK-92: 68.3 ⁇ 9.1 ; NK-92/5.28.z: 21 ⁇ 4.9; irradiated NK-92/5.28.z: 14.4 ⁇ 5.5; ⁇ 0.01) (Figure 5B).
  • NK-92/5.28.Z cells demonstrate specific antitumor activity of systemically applied NK-92/5.28.Z cells against ErbB2-expressing tumor cells in a model reflecting disseminated disease. Importantly, viability and functionality of NK-92/5.28.Z cells were transiently preserved after ⁇ -irradiation at a dose that prevents further effector cell replication, permitting target cell recognition and killing in vivo.
  • Hynes NE, Lane HA. ERBB receptors and cancer the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341-354.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une cellule ou une lignée cellulaire NK-92 spécifique de ErbB2 contenant un vecteur lentiviral codant pour un récepteur d'antigène chimère et de préférence deux loci d'intégration de vecteur dans son génome cellulaire. La présente invention concerne en outre l'utilisation de la cellule ou de la lignée cellulaire NK-92 spécifique de ErbB2 dans la prévention et/ou le traitement du cancer, de préférence de cancers exprimant la protéine ErbB2. La présente invention concerne en outre l'utilisation de la cellule ou de la lignée cellulaire NK-92 spécifique de ErbB2 comme agent thérapeutique cellulaire ciblé et/ou pour l'immunothérapie adoptive du cancer. La présente invention concerne en outre un procédé pour générer une cellule ou une lignée cellulaire NK-92 spécifique de ErbB2 ainsi qu'un procédé d'identification d'une cellule ou d'une lignée cellulaire NK-92 spécifique de ErbB2 et une cellule ou une lignée cellulaire NK-92 spécifique de ErbB2 obtenue ou identifiée par les procédés ainsi que leurs utilisations.
EP15730150.8A 2014-06-18 2015-06-18 Cellules nk-92 exprimant car en tant qu'agents thérapeutiques cellulaires Active EP3157958B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14173020 2014-06-18
PCT/EP2015/063674 WO2015193411A1 (fr) 2014-06-18 2015-06-18 Cellules nk-92 exprimant car comme agents thérapeutiques cellulaires

Publications (2)

Publication Number Publication Date
EP3157958A1 true EP3157958A1 (fr) 2017-04-26
EP3157958B1 EP3157958B1 (fr) 2020-05-06

Family

ID=50972557

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15730150.8A Active EP3157958B1 (fr) 2014-06-18 2015-06-18 Cellules nk-92 exprimant car en tant qu'agents thérapeutiques cellulaires

Country Status (10)

Country Link
US (3) US10550197B2 (fr)
EP (1) EP3157958B1 (fr)
JP (1) JP2017525385A (fr)
KR (1) KR20170018450A (fr)
CN (1) CN106459916A (fr)
AU (1) AU2015276136A1 (fr)
CA (1) CA2951355C (fr)
ES (1) ES2806776T3 (fr)
IL (1) IL249424A0 (fr)
WO (1) WO2015193411A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160113158A (ko) 2014-01-27 2016-09-28 몰레큘러 템플레이츠, 인코퍼레이션. 폴리펩티드를 전달하는 mhc 클래스 i 항원결정기
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
CN106459914B (zh) 2014-05-15 2020-11-06 新加坡国立大学 经修饰的自然杀伤细胞及其用途
CN106604934A (zh) 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
US10550197B2 (en) * 2014-06-18 2020-02-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus CAR-expressing NK-92 cells as cell therapeutic agents
GB201501175D0 (en) 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
AU2016215205B2 (en) * 2015-02-05 2021-10-21 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
KR102647100B1 (ko) 2015-05-30 2024-03-13 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드 및 이를 포함하는 세포-표적화 분자
US20190046570A1 (en) * 2016-02-05 2019-02-14 Nant Holdings Ip, Llc Compositions and Methods for Recombinant CXADR Expression
EP3452580B1 (fr) * 2016-05-02 2023-08-16 Cerus Corporation Compositions et méthodes pour thérapies par cellules nk améliorées
US20200316118A1 (en) 2016-05-19 2020-10-08 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
CN107988164B (zh) 2016-10-26 2020-07-07 阿思科力(苏州)生物科技有限公司 一种pd-1 car nk-92细胞及其制备方法与应用
IL302130A (en) * 2016-12-07 2023-06-01 Molecular Templates Inc Shiga toxin A subunit activator polypeptides, Shiga toxin activator scaffolds and cell-targeting molecules for site-specific conjugation
IL267990B2 (en) 2017-01-25 2024-04-01 Molecular Templates Inc Cell-targeted molecules containing Shiga toxin A subunit activators and nonimmune CD8 T-cell epitopes
US11896616B2 (en) 2017-03-27 2024-02-13 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
MX2019011514A (es) 2017-03-27 2020-01-27 Nat Univ Singapore Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales.
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
US20210187024A1 (en) * 2017-11-01 2021-06-24 Nantkwest, Inc. NK-92 Cells to Stimulate Anti-Cancer Vaccine
CN109810995B (zh) * 2017-12-06 2020-10-02 阿思科力(苏州)生物科技有限公司 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用
US20210054409A1 (en) * 2018-02-09 2021-02-25 National University Of Singapore Adhesion Receptor Constructs and Uses Thereof in Natural Killer Cell Immunotherapy
SG10201801219VA (en) * 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
KR102287180B1 (ko) 2019-10-01 2021-08-09 충북대학교 산학협력단 Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
GB2604813A (en) * 2019-11-20 2022-09-14 Immunitybio Inc Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
CN113005151A (zh) * 2021-03-12 2021-06-22 广东药科大学 一种kdr-car-nk细胞的制备方法及其应用
CN114106203A (zh) * 2021-11-26 2022-03-01 杭州乾合细胞生物科技有限公司 一种含有靶向Her-2 CAR序列的核酸构建体及其应用
CN116656614A (zh) * 2022-02-17 2023-08-29 杭州乾合细胞生物科技有限公司 一种靶向Her-2的CAR-NK细胞及其应用
CN114574447B (zh) * 2022-03-10 2023-10-20 中国海洋大学 Her2靶向的增强型抗肿瘤nk细胞、其制备方法及其应用
CN114805584B (zh) * 2022-06-30 2022-09-09 上海优替济生生物医药有限公司 抗原结合蛋白及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1007630B1 (fr) 1997-04-30 2006-04-19 Hans Klingemann Lignees de cellules tueuses naturelles et procedes d'utilisation
CA3052445C (fr) 2004-07-10 2023-08-22 Kerry S. Campbell Lignees de cellules tueuses, naturelles, humaines et genetiquement modifiees
EP3012268B1 (fr) 2010-09-08 2017-11-15 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Recepteurs d'antigenes chimeriques comprenant une region charniere optimisee
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
US10550197B2 (en) * 2014-06-18 2020-02-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus CAR-expressing NK-92 cells as cell therapeutic agents

Also Published As

Publication number Publication date
EP3157958B1 (fr) 2020-05-06
IL249424A0 (en) 2017-02-28
CA2951355A1 (fr) 2015-12-23
US10550197B2 (en) 2020-02-04
WO2015193411A1 (fr) 2015-12-23
JP2017525385A (ja) 2017-09-07
US9920132B2 (en) 2018-03-20
ES2806776T3 (es) 2021-02-18
US20170129967A1 (en) 2017-05-11
CN106459916A (zh) 2017-02-22
US20180282427A1 (en) 2018-10-04
KR20170018450A (ko) 2017-02-17
US20170283507A1 (en) 2017-10-05
CA2951355C (fr) 2023-10-31
AU2015276136A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
US9920132B2 (en) Car-expressing NK-92 cells as cell therapeutic agents
Bailey et al. Gene editing for immune cell therapies
AU2019214163B2 (en) Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
JP2022093564A (ja) キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法
ES2927366T3 (es) Vector de expresión de CAR y células T que expresan CAR
JP6682509B2 (ja) キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
US11896616B2 (en) Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
Tomuleasa et al. Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia
US20140302608A1 (en) Modified Effector Cell (or Chimeric Receptor) for Treating Disialoganglioside GD2-Expressing Neoplasia
JP7232447B2 (ja) メモリー機能を有するｔ細胞又はｂ細胞の増強剤、悪性腫瘍再発抑制剤、及びｔ細胞又はｂ細胞にメモリー機能を誘導する誘導剤
KR20220042161A (ko) Suv39h1에 결함이 있는 면역 세포
US20230390392A1 (en) Multiplex gene edited cells for cd70-directed cancer immunotherapy
CN107602703A (zh) 靶向人EpCAM的基因工程化淋巴细胞及其制备方法和用途
CN111065410A (zh) 用于改善过继细胞疗法的方法
WO2022099026A1 (fr) Compositions et méthodes de traitement du cancer par immunothérapie anti-cd19/cd22
US20230355691A1 (en) Novel recombinant vaccinia virus and use thereof
Kaur et al. Role of Natural Killer Cells as Cell-Based Immunotherapy in Oral Tumor Eradication and Differentiation Both In Vivo and In Vitro
CN116376920A (zh) Ceacam5靶向的car-t细胞的制备方法及应用
CN117295820A (zh) 以ccr8作为抗原识别的嵌合抗原受体
Koval et al. NK-cell based delivery of anticancer therapeutics

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GREZ, MANUEL

Inventor name: WELS, WINFRIED

Inventor name: SCHOENFELD, KURT

Inventor name: ZHANG, CONGCONG

Inventor name: TONN, TORSTEN

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180104

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20191206

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TONN, TORSTEN

Inventor name: SCHOENFELD, KURT

Inventor name: ZHANG, CONGCONG

Inventor name: WELS, WINFRIED

Inventor name: GREZ, MANUEL

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1266594

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015052184

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200906

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200907

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200806

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200806

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1266594

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015052184

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2806776

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20210218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200618

26N No opposition filed

Effective date: 20210209

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200618

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200630

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200506

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230412

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230515

Year of fee payment: 9

Ref country code: IT

Payment date: 20230510

Year of fee payment: 9

Ref country code: FR

Payment date: 20230421

Year of fee payment: 9

Ref country code: DE

Payment date: 20230630

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230427

Year of fee payment: 9

Ref country code: ES

Payment date: 20230711

Year of fee payment: 9

Ref country code: CH

Payment date: 20230702

Year of fee payment: 9